Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Acadia Pharmaceutica (NQ: ACAD )

47.31 USD -1.38 (-2.83%)
Official Closing Price Updated: 7:40 PM EST, Feb 25, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Acadia Pharmaceutica

< Previous 1 2 3 4 5 6 7 8 9
...
33 34 Next >
Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced financial results for the fourth quarter and full year ended December 31, 2020. 
From Business Wire News Releases
Acadia Pharmaceuticals Recognizes National Caregiver’s Day with Launch of MoreThanMemoryLoss.com
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the launch of MoreThanMemoryLoss.com, a new website with educational resources designed to help caregivers and people living with dementia to... 
From Business Wire News Releases
Acadia Pharmaceuticals to Present at Upcoming Investor Conferences
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at the following investor conferences: 
From Business Wire News Releases
Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2020 Financial Results on February 24, 2021
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report fourth quarter and full year 2020 financial results on Wednesday, February 24, 2021, after the close of the U.S. financial... 
From Business Wire News Releases
Acadia Pharmaceuticals Announces Commercial Leadership Change
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Michael Yang, Executive Vice President and Chief Commercial Officer, will be leaving the organization effective January 29, 2021 to... 
From Business Wire News Releases
Shuman Glenn & Stecker Investigates Acadia Pharmaceuticals, Inc.
Shuman, Glenn & Stecker Investigates Acadia Pharmaceuticals, Inc. 
From Business Wire News Releases
Acadia Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference on January 12, 2021
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021, at 2:00 p.m. Eastern Time, followed by... 
From Business Wire News Releases
Acadia Pharmaceuticals to Present at the Stifel 2020 Virtual Healthcare Conference on November 17, 2020
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the Stifel 2020 Virtual Healthcare Conference on Tuesday, November 17, 2020, at 3:20 p.m. Eastern Time. 
From Business Wire News Releases
Acadia Pharmaceuticals Reports Third Quarter 2020 Financial Results
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system... 
From Business Wire News Releases
Acadia Pharmaceuticals to Present New Scientific Data on Pimavanserin in Neurodegenerative Diseases at the 13th Clinical Trials on Alzheimer's Disease (CTAD) Conference
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that scientific presentations highlighting new analyses of pimavanserin clinical study data in dementia-related psychosis and... 
From Business Wire News Releases
Acadia Pharmaceuticals to Announce Third Quarter 2020 Financial Results on November 4, 2020
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report third quarter financial results on Wednesday, November 4, 2020, after the close of the U.S. financial markets. Acadia’s... 
From Business Wire News Releases
The Lewy Body Dementia Association and Acadia Pharmaceuticals to Release Educational Version of the Highly Acclaimed Robin Williams Documentary, “Robin’s Wish”
The Lewy Body Dementia Association (LBDA) and Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced today an exclusive partnership on the production and release of a disease education adaptation of the... 
From Business Wire News Releases
Acadia Pharmaceuticals Appoints Elizabeth Garofalo, M.D. to Board of Directors
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Elizabeth (Betsy) Garofalo, M.D. to its Board of Directors. Dr. Garofalo is a biopharma executive with more than 25 years... 
From Business Wire News Releases
(ACAD) Alert: Johnson Fistel Announces Shareholder Class Action Against ACADIA Pharmaceuticals Survives Motion to Dismiss; Should Management be Held Accountable for Investors Losses?
Johnson Fistel, LLP is investigating potential claims on behalf of ACADIA Pharmaceuticals Inc. (NasdaqGS: ACAD) ("ACADIA" or the "Company") against certain of its officers and directors. Specifically,... 
From PR Newswire
ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at the following upcoming virtual investor conferences: 
From Business Wire News Releases
ACADIA Pharmaceuticals Appoints Gudarz Davar, M.D., as Executive Vice President and Head of Research and Development
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Dr. Gudarz Davar as Executive Vice President and Head of Research and Development. Dr. Davar will be responsible for... 
From Business Wire News Releases
ACADIA Pharmaceuticals Acquires CerSci Therapeutics, Adds Novel Pain Program to Portfolio
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the acquisition of CerSci Therapeutics, a clinical-stage biotechnology company with worldwide rights to a portfolio of novel compounds for... 
From Business Wire News Releases
ACADIA Pharmaceuticals to Present at The JMP Securities CNS Forum on August 19, 2020
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at The JMP Securities CNS Forum on Wednesday, August 19, 2020, at 11:00 a.m. Eastern Time. 
From Business Wire News Releases
ACADIA Pharmaceuticals Reports Second Quarter 2020 Financial Results
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system... 
From Business Wire News Releases
SHAREHOLDER ALERT: Stephens & Stephens LLP Investigating the Officers and Directors of ACADIA Pharmaceuticals Inc. (ACAD)
Stephens & Stephens LLP is investigating the officers and directors of ACADIA Pharmaceuticals Inc. (NasdaqGS: ACAD) for breach of fiduciary duties on the part of its directors and management. 
From Business Wire News Releases
People with Dementia and Caregivers Share the Significant Burden of Visual Hallucinations and Paranoid Delusions, New Survey Highlights
UsAgainstAlzheimer’s, the Lewy Body Dementia Association and ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the results of a qualitative and quantitative survey that explored the impact of... 
From Business Wire News Releases
ACADIA Pharmaceuticals to Announce Second Quarter 2020 Financial Results on August 5, 2020
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report second quarter financial results on Wednesday, August 5, 2020, after the close of the U.S. financial markets. ACADIA’s... 
From Business Wire News Releases
ACADIA Pharmaceuticals Announces U.S. FDA Accepted for Filing the Supplemental New Drug Application for NUPLAZID® (pimavanserin) for the Treatment of Hallucinations and Delusions Associated with Demen
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing its supplemental New Drug Application (sNDA) for NUPLAZID®... 
From Business Wire News Releases
ACADIA Pharmaceuticals Announces Top-line Results from the Phase 3 CLARITY Study Evaluating Pimavanserin for the Adjunctive Treatment of Major Depressive Disorder
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced top-line results from its 298 patient Phase 3 CLARITY study which combined two identical, double-blind, placebo-controlled studies evaluating... 
From Business Wire News Releases
ACADIA Pharmaceuticals Submits Supplemental New Drug Application to U.S. FDA for NUPLAZID® (pimavanserin) for the Treatment of Hallucinations and Delusions Associated with Dementia-Related Psychosis
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) announced today that the company submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) to support a potential... 
From Business Wire News Releases
ACADIA Pharmaceuticals to Present at the Goldman Sachs 41st Annual Global Healthcare Conference on June 9, 2020
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the Goldman Sachs 41st Annual Global Healthcare Conference on Tuesday, June 9, 2020, at 4:40 p.m. Eastern Time. 
From Business Wire News Releases
ACADIA Pharmaceuticals Appoints Mark Schneyer as Senior Vice President, Business Development and Chief Business Officer
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) announced today announced that Mark Schneyer has been appointed to the newly created position of Senior Vice President, Business Development and Chief... 
From Business Wire News Releases
ACADIA Pharmaceuticals to Combine CLARITY-2 and CLARITY-3 Phase 3 Studies Evaluating Pimavanserin for the Adjunctive Treatment of Major Depressive Disorder
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) announced today that following positive feedback from the U.S. Food and Drug Administration the company plans to combine its CLARITY-2 and CLARITY-3 Phase 3... 
From Business Wire News Releases
ACADIA Pharmaceuticals to Present Pimavanserin Clinical Data at the 2020 American Society of Clinical Psychopharmacology Virtual Annual Meeting
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that multiple scientific presentations and abstracts evaluating pimavanserin in clinical studies for the treatment of various central nervous... 
From Business Wire News Releases
ACADIA Pharmaceuticals Reports First Quarter 2020 Financial Results
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system... 
From Business Wire News Releases
< Previous 1 2 3 4 5 6 7 8 9
...
33 34 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.